Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells

被引：55

作者：

Gao, Shan ^{[1
]}

Mobley, Aaron ^{[1
]}

Miller, Claudia ^{[1
]}

Boklan, Jessica ^{[2
]}

Chandra, Joya ^{[1
]}

机构：

[1] Childrens Canc Hosp, MD Anderson Canc Ctr, Dept Pediat Res, Houston, TX 77030 USA

[2] Phoenix Childrens Hosp, Ctr Canc & Blood Disorders, Phoenix, AZ USA

来源：

LEUKEMIA RESEARCH | 2008年 / 32卷 / 05期

关键词：

MS-275; 5-azacytidine; historic deacetylase inhibitor; DNA methyltransferase; reactive oxygen species;

D O I：

10.1016/j.leukres.2007.09.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Epigenetic modifiers are currently in clinical use for various tumor types. Recently, numerous studies supporting the combination of histone deacetylase inhibitors (HDACi) and DNA methyltransferase inhibitors have emerged, encouraging early clinical trials of these agents together. Here we show that MS-275, an HDACi, and 5-azacytidine, a methyltransferase inhibitor, display synergistic cytotoxicity and apoptosis in AML and ALL cells. Intracellular production of reactive oxygen species (ROS), such as superoxide and hydrogen peroxide, is a novel marker for this synergism in ALL cells. These data suggest that assessment of oxidative stress can serve as a marker of the concerted action of MS-275 and 5-azacytidine. (C) 2007 Elsevier Ltd. All rights reserved.

引用

页码：771 / 780

页数：10

共 33 条

[1] Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue [J].

Acharya, MR ;

Figg, WD .

CANCER BIOLOGY & THERAPY, 2004, 3 (08) :719-720

[2] The role of decitabine in the treatment of myelodysplastic syndromes [J].

Atallah, Ehab ;

Kantarjian, Hagop ;

Garcia-Manero, Guillermo .

EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (01) :65-73

[3] Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells [J].

Bovenzi, V ;

Momparler, RL .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (01) :71-76

[4] Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance [J].

Chandra, J ;

Tracy, J ;

Loegering, D ;

Flatten, K ;

Verstovsek, S ;

Beran, M ;

Gorre, M ;

Estrov, Z ;

Donato, N ;

Talpaz, M ;

Sawyers, C ;

Bhalla, K ;

Karp, J ;

Sausville, E ;

Kaufmann, SH .

BLOOD, 2006, 107 (06) :2501-2506

[5] Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells [J].

Chandra, J ;

Hackbarth, J ;

Le, S ;

Loegering, D ;

Bone, N ;

Bruzek, LM ;

Narayanan, VL ;

Adjei, AA ;

Kay, NE ;

Tefferi, A ;

Karp, JE ;

Sausville, EA ;

Kaufmann, SH .

BLOOD, 2003, 102 (13) :4512-4519

[6] QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].

CHOU, TC ;

TALALAY, P .

ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55

[7] Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine [J].

Donadelli, Massimo ;

Costanzo, Chiara ;

Beghelli, Stefania ;

Scupoli, Maria Teresa ;

Dandrea, Mario ;

Bonora, Antonio ;

Piacentini, Paolo ;

Budillon, Alfredo ;

Caraglia, Michele ;

Scarpa, Aldo ;

Palmieri, Marta .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2007, 1773 (07) :1095-1106

[8] Epigenetics in human disease and prospects for epigenetic therapy [J].

Egger, G ;

Liang, GN ;

Aparicio, A ;

Jones, PA .

NATURE, 2004, 429 (6990) :457-463

[9] Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia [J].

Garcia-Manero, Guillermo ;

Kantarjian, Hagop M. ;

Sanchez-Gonzalez, Blanca ;

Yang, Hui ;

Rosner, Gary ;

Verstovsek, Srdan ;

Rytting, Michael ;

Wierda, William G. ;

Ravandi, Farhad ;

Koller, Charles ;

Xiao, Lianchun ;

Faderl, Stefan ;

Estrov, Zeev ;

Cortes, Jorge ;

O'Brien, Susan ;

Estey, Elihu ;

Bueso-Ramos, Carlos ;

Fiorentino, Jackie ;

Jabbour, Elias ;

Issa, Jean-Pierre .

BLOOD, 2006, 108 (10) :3271-3279

[10] Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias [J].

Gojo, Ivana ;

Jiemjit, Anchalee ;

Trepel, Jane B. ;

Sparreboom, Alex ;

Figg, William D. ;

Rollins, Sandra ;

Tidwell, Michael L. ;

Greer, Jacqueline ;

Chung, Eun Joo ;

Lee, Min-Jung ;

Gore, Steven D. ;

Sausville, Edward A. ;

Zwiebel, James ;

Karp, Judith E. .

BLOOD, 2007, 109 (07) :2781-2790

← 1 2 3 4 →